In summary, by combining bioinformatic and experimental studies, we found that reduced expression level of CYR61 may serve as a new prognostic marker for ER-positive BRCA, and revealed that CYR61 acts as a tumor inhibitor by impeding cancer cell malignant transformation and remodeling the TIME. This evidence concerns the gene CCN1 and cancer.